ArticleVaccines2026

Comment on Kura et al. Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States.

Erin N Hodges et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.